特发性肺纤维化治疗药物的最新研究进展  

The Progress about Therapeutic Drug of Idiopathic Pulmonary Fibrosis

作　　者：韩文阳[1] 王文杰[1] 

机构地区：[1]中国医学科学院中国协和医科大学药物研究所,北京100050

出　　处：《医学综述》2006年第8期497-499,共3页Medical Recapitulate

摘　　要：特发性肺纤维化是一种较为严重的慢性肺间质性疾病,近年来,随着对本病发病机制和病理生理变化的深入研究和分子生物学技术的应用,治疗上有了新的突破。本文就其治疗药物研究的最新进展,从抗氧化酶制剂、抗细胞因子、血小板活化因子受体拮抗剂、中药等方面作一综述。Idiopathic pulmonary fibrosis （IPF） is a severe chronic interstitium disease in the lung. Along with the research about the pathogenesis and pathophysiology of IPF and the application of molecular biological technique, the treatment of IPF has achieved a significant breakthrough in recent years. The advancements in antioxidant, anti-cytokine, platelet-activating factor inhibitor and traditional Chinese medicine are reviewed in this paper.

关 键 词：特发性肺纤维化 细胞因子 中药 抗氧化剂 治疗 

分 类 号：R563[医药卫生—呼吸系统]